Switch to:
Also traded in: Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.06
MYL's Cash-to-Debt is ranked lower than
94% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.09 vs. MYL: 0.06 )
Ranked among companies with meaningful Cash-to-Debt only.
MYL' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: 6.63 Max: N/A
Current: 0.06
Equity-to-Asset 0.34
MYL's Equity-to-Asset is ranked lower than
86% of the 734 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. MYL: 0.34 )
Ranked among companies with meaningful Equity-to-Asset only.
MYL' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.19  Med: 0.83 Max: 0.94
Current: 0.34
0.19
0.94
Interest Coverage 1.57
MYL's Interest Coverage is ranked lower than
93% of the 635 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 105.95 vs. MYL: 1.57 )
Ranked among companies with meaningful Interest Coverage only.
MYL' s Interest Coverage Range Over the Past 10 Years
Min: 0.83  Med: 3.29 Max: 8.18
Current: 1.57
0.83
8.18
Piotroski F-Score: 4
Altman Z-Score: 1.24
Beneish M-Score: -2.69
WACC vs ROIC
9.85%
4.88%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 7.09
MYL's Operating Margin % is ranked lower than
57% of the 744 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.42 vs. MYL: 7.09 )
Ranked among companies with meaningful Operating Margin % only.
MYL' s Operating Margin % Range Over the Past 10 Years
Min: 5.8  Med: 15.91 Max: 26.53
Current: 7.09
5.8
26.53
Net Margin % 4.59
MYL's Net Margin % is ranked lower than
58% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.16 vs. MYL: 4.59 )
Ranked among companies with meaningful Net Margin % only.
MYL' s Net Margin % Range Over the Past 10 Years
Min: -3.53  Med: 8.88 Max: 13.48
Current: 4.59
-3.53
13.48
ROE % 4.82
MYL's ROE % is ranked lower than
58% of the 768 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.86 vs. MYL: 4.82 )
Ranked among companies with meaningful ROE % only.
MYL' s ROE % Range Over the Past 10 Years
Min: -14.72  Med: 14.08 Max: 29.99
Current: 4.82
-14.72
29.99
ROA % 1.70
MYL's ROA % is ranked lower than
61% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.49 vs. MYL: 1.70 )
Ranked among companies with meaningful ROA % only.
MYL' s ROA % Range Over the Past 10 Years
Min: -2.47  Med: 4.52 Max: 7.1
Current: 1.7
-2.47
7.1
ROC (Joel Greenblatt) % 16.09
MYL's ROC (Joel Greenblatt) % is ranked higher than
50% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.40 vs. MYL: 16.09 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
MYL' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 14.32  Med: 28.81 Max: 47.2
Current: 16.09
14.32
47.2
3-Year Revenue Growth Rate 6.70
MYL's 3-Year Revenue Growth Rate is ranked higher than
53% of the 607 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.70 vs. MYL: 6.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
MYL' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -6.1  Med: 15.2 Max: 54.5
Current: 6.7
-6.1
54.5
3-Year EBITDA Growth Rate 0.30
MYL's 3-Year EBITDA Growth Rate is ranked lower than
67% of the 583 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.40 vs. MYL: 0.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
MYL' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -20.4  Med: 11.1 Max: 107.9
Current: 0.3
-20.4
107.9
3-Year EPS without NRI Growth Rate -16.50
MYL's 3-Year EPS without NRI Growth Rate is ranked lower than
78% of the 551 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. MYL: -16.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
MYL' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -29.1  Med: 8.1 Max: 110.4
Current: -16.5
-29.1
110.4
GuruFocus has detected 4 Warning Signs with Mylan NV $MYL.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» MYL's 30-Y Financials

Financials (Next Earnings Date: 2017-08-10 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

MYL Guru Trades in Q2 2016

Lee Ainslie 2,294,698 sh (New)
David Einhorn 4,945,000 sh (+71.11%)
Paul Tudor Jones 9,355 sh (+44.93%)
Vanguard Health Care Fund 27,965,385 sh (+4.82%)
Pioneer Investments 54,144 sh (unchged)
Paul Tudor Jones 80,000 sh (unchged)
John Paulson 1,030,400 sh (unchged)
Tom Russo Sold Out
Joel Greenblatt Sold Out
Scott Black 41,144 sh (-3.21%)
John Paulson 22,028,061 sh (-5.60%)
Mario Gabelli 14,000 sh (-17.65%)
» More
Q3 2016

MYL Guru Trades in Q3 2016

Joel Greenblatt 21,460 sh (New)
David Einhorn 6,400,000 sh (+29.42%)
Paul Tudor Jones 10,900 sh (+16.52%)
Mario Gabelli 16,012 sh (+14.37%)
Vanguard Health Care Fund 29,148,837 sh (+4.23%)
Pioneer Investments 54,839 sh (+1.28%)
Scott Black 41,176 sh (+0.08%)
John Paulson 940,400 sh (unchged)
John Paulson 21,811,661 sh (-0.98%)
Lee Ainslie 1,336,436 sh (-41.76%)
» More
Q4 2016

MYL Guru Trades in Q4 2016

Jim Simons 1,504,000 sh (New)
First Pacific Advisors 3,085,731 sh (New)
David Tepper 3,275,000 sh (New)
Lee Ainslie 3,799,281 sh (+184.28%)
David Einhorn 8,670,307 sh (+35.47%)
Vanguard Health Care Fund 30,084,537 sh (+3.21%)
Mario Gabelli 16,512 sh (+3.12%)
John Paulson 904,200 sh (unchged)
Joel Greenblatt Sold Out
Scott Black 40,841 sh (-0.81%)
Pioneer Investments 54,144 sh (-1.27%)
John Paulson 20,602,500 sh (-5.54%)
Paul Tudor Jones 5,500 sh (-49.54%)
» More
Q1 2017

MYL Guru Trades in Q1 2017

Richard Pzena 7,262,316 sh (New)
Steven Cohen 3,602,271 sh (New)
Joel Greenblatt 648,342 sh (New)
Paul Tudor Jones 99,063 sh (+1701.15%)
First Pacific Advisors 5,349,600 sh (+73.37%)
Jim Simons 2,488,400 sh (+65.45%)
David Einhorn 8,692,307 sh (+0.25%)
Steven Cohen 40,000 sh (unchged)
John Paulson 200,000 sh (unchged)
Scott Black 40,821 sh (-0.05%)
Vanguard Health Care Fund 29,295,842 sh (-2.62%)
Mario Gabelli 14,500 sh (-12.19%)
John Paulson 17,274,387 sh (-16.15%)
Pioneer Investments 35,014 sh (-35.33%)
David Tepper 1,900,000 sh (-41.98%)
Lee Ainslie 1,545,448 sh (-59.32%)
» More
» Details

Insider Trades

Latest Guru Trades with MYL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:OTCPK:SGIOF, OTCPK:MKGAY, OTCPK:ESALF, OTCPK:MTZXF, NYSE:ZTS, NYSE:TEVA, OTCPK:SFOSF, NYSE:PRGO, OTCPK:IPSEY, OTCPK:HLUYY, OTCPK:APNHF, NYSE:RDY, OTCPK:HKMPY, OTCPK:HYPMY, NYSE:PTHN, NYSE:VRX, NYSE:TARO, OTCPK:STDAF, NYSE:CTLT, NAS:AKRX » details
Traded in other countries:6MY.Germany, MYL1.Switzerland, 0R5P.UK,
Headquarter Location:UK
Mylan NV is a generic pharmaceutical manufacturer which develops, licenses, manufactures, markets and distributes generic, over-the-counter (OTC) products in a variety of dosage forms and therapeutic categories.

Mylan is the world's fourth-largest generic pharmaceutical manufacturer with operations in the United States, Europe, Asia, Middle East, Africa, and Australia. Generic drug sales comprise approximately 84% of revenue. Remaining sales come from a handful of branded products, primarily the epinephrine injector EpiPen. Mylan also owns Matrix, an Indian active pharmaceutical ingredient manufacturer.

Guru Investment Theses on Mylan NV

John Keeley Comments on Mylan Labs - Apr 26, 2016

Mylan Labs (NASDAQ:MYL), another detractor, announced a slightly weaker quarter than expected as well as the acquisition of European-based Meda, which appeared expensive in our opinion. We met with management at a recent investor conference and discussed their failed hostile takeover attempt of Perrigo (PRGO), their rebuffing of Teva Pharmaceutical’s simultaneous acquisition offer, and its acquisition of Meda. Even though we believe the stock is relatively cheap, we did not receive satisfactory responses to our questions; as such we elected to sell the position.



From Keeley All Cap Value Fund first quarter 2016 commentary.



Check out John Keeley latest stock trades

Keeley Funds Comments on Mylan N.V. - Feb 03, 2016

The Fund’s largest contributor during the quarter was Mylan N.V (NASDAQ:MYL) which rose over 34 percent and added 84 basis points of return to the Fund. Shares were initially weak following its failed bid to merge with rival Perrigo (NYSE:PRGO). We viewed the failed bid as a positive as we were skeptical of the synergies between the two companies. We increased our exposure to the stock during the weakness as we believe the shares are very cheap on a valuation basis.



From the Keeley All Cap Value Fund 4th quarter 2015 shareholder letter.



Check out John Keeley latest stock trades

David Einhorn Comments on Mylan - Jan 19, 2016

We initiated a position in Mylan (NASDAQ:MYL), a global generic pharmaceuticals company. MYLshares fell 29% in the first three quarters of 2015 and over 45% from their mid-year highsafter generics rival Teva abandoned a hostile takeover bid for the company. During the fall,the market became overly focused on a series of overhangs including potential earningsdilution from a proposed and ultimately failed buyout of Perrigo (a private-label OTC business); corporate governance concerns including an unusual takeover-defense mechanism;and widespread unease about the pharmaceutical sector amidst scrutiny of specialty pharmaceutical manufacturers like Valeant.

We acknowledge eventual headwinds for the company’s branded EpiPen product, whichcould encounter competition from generics in late 2016. However, we see medium-termupside from a competitor recall, an announced share repurchase, and board review ofcorporate governance complaints. Ultimately, we expect MYL to earn close to $7 per share in2018, driven by a robust pipeline of respiratory, injectable and biologic drugs and by furthercapital deployment including share repurchases. We initiated our position at an average priceof $45.32, about 9x 2016 consensus EPS estimates. MYL shares ended the quarter at $54.07.

From David Einhorn (Trades, Portfolio)'s Green Light Capital fourth quarter 2015 shareholder letter.

Check out David Einhorn latest stock trades

Keeley Funds Comments on Mylan NV - Nov 03, 2015

The largest detractor during the quarter was in the health care sector after Mylan NV (NASDAQ:MYL) fell over 40 percent and cost the Fund 83 basis points in performance. The key development that pressured the stock was when rival TEVA Pharmaceutical (NYSE:TEVA) removed its takeover bid and instead acquired Allergan PLC’s (NYSE:AGN) generic business. Mylan remains interested in acquiring Perrigo (NYSE:PRGO) who prefers to remain independent. In addition, all of healthcare, and drug makers specifically, are seeing considerable selling pressure due to Valiant Pharmaceutical’s (NYSE:VRX) specialty pharmacy sales and Mylan does not use specialty pharmacies. Lastly, political rhetoric about price controls in health care is being bandied about by the Democratic frontrunner and those comments have had a negative impact on the entire industry.





From the Keeley All-Cap Value Fund commentary on third quarter 2015.



Check out John Keeley latest stock trades

Top Ranked Articles about Mylan NV

Richard Pzena Invests in 3 Health Care Companies Guru releases 1st-quarter portfolio
Richard Pzena (Trades, Portfolio) gained 14 new holdings during the first quarter. Among them were three health care stocks, including Mylan NV(NASDAQ:MYL), Cardinal Health Inc. (NYSE:CAH) and Biogen Inc. (NASDAQ:BIIB). Read more...
Abbott Sells More Mylan Holdings Abbott sold 44 million shares for a total consideration of $1.83 billion
Abbott (NYSE:ABT), the U.S. global health care company headquartered in Lake Bluff, Illinois, “confirmed that it sold 44 million shares of Mylan (NASDAQ:MYL) at $41.60 on March 23,” writes StreetInsider.com. Read more...
Mylan Posts Loss Amid Investigation, Settlement Pharmaceutical company joins Valeant in reporting a loss
Mylan (NASDAQ:MYL) released its third-quarter earnings Wednesday, reporting a quarterly loss and revenue growth that was below expectations. Read more...
David Einhorn Speaks on Passive Investing, Mylan, His Cheapest Stock, the Fed GuruFocus covered Einhorn at Great Investors' Best Ideas conference
Greenlight Capital hedge fund manager David Einhorn (Trades, Portfolio) joined nine other famed investors on Tuesday to talk about stocks at the annual Great Investors’ Best Ideas Investment Symposium in Dallas. Read more...

Ratios

vs
industry
vs
history
PE Ratio 38.81
MYL's PE Ratio is ranked lower than
68% of the 556 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.48 vs. MYL: 38.81 )
Ranked among companies with meaningful PE Ratio only.
MYL' s PE Ratio Range Over the Past 10 Years
Min: 7.32  Med: 25.52 Max: 112.56
Current: 38.81
7.32
112.56
Forward PE Ratio 7.26
MYL's Forward PE Ratio is ranked higher than
87% of the 202 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.39 vs. MYL: 7.26 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 38.81
MYL's PE Ratio without NRI is ranked lower than
68% of the 544 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.85 vs. MYL: 38.81 )
Ranked among companies with meaningful PE Ratio without NRI only.
MYL' s PE Ratio without NRI Range Over the Past 10 Years
Min: 7.32  Med: 25.52 Max: 112.56
Current: 38.81
7.32
112.56
Price-to-Owner-Earnings 291.10
MYL's Price-to-Owner-Earnings is ranked lower than
96% of the 293 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.45 vs. MYL: 291.10 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
MYL' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 13.37  Med: 33.79 Max: 332.21
Current: 291.1
13.37
332.21
PB Ratio 1.91
MYL's PB Ratio is ranked higher than
69% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.03 vs. MYL: 1.91 )
Ranked among companies with meaningful PB Ratio only.
MYL' s PB Ratio Range Over the Past 10 Years
Min: 0.64  Med: 2.55 Max: 7.02
Current: 1.91
0.64
7.02
PS Ratio 1.86
MYL's PS Ratio is ranked higher than
67% of the 721 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. MYL: 1.86 )
Ranked among companies with meaningful PS Ratio only.
MYL' s PS Ratio Range Over the Past 10 Years
Min: 0.4  Med: 1.78 Max: 3.95
Current: 1.86
0.4
3.95
Price-to-Free-Cash-Flow 15.93
MYL's Price-to-Free-Cash-Flow is ranked higher than
67% of the 226 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.83 vs. MYL: 15.93 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
MYL' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.82  Med: 20.15 Max: 115.12
Current: 15.93
8.82
115.12
Price-to-Operating-Cash-Flow 10.10
MYL's Price-to-Operating-Cash-Flow is ranked higher than
76% of the 288 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.62 vs. MYL: 10.10 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
MYL' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.07  Med: 11.94 Max: 40.9
Current: 10.1
6.07
40.9
EV-to-EBIT 51.10
MYL's EV-to-EBIT is ranked lower than
90% of the 776 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.99 vs. MYL: 51.10 )
Ranked among companies with meaningful EV-to-EBIT only.
MYL' s EV-to-EBIT Range Over the Past 10 Years
Min: -10.3  Med: 19 Max: 74.5
Current: 51.1
-10.3
74.5
EV-to-EBITDA 15.23
MYL's EV-to-EBITDA is ranked lower than
53% of the 797 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.26 vs. MYL: 15.23 )
Ranked among companies with meaningful EV-to-EBITDA only.
MYL' s EV-to-EBITDA Range Over the Past 10 Years
Min: -17.7  Med: 11.1 Max: 23.3
Current: 15.23
-17.7
23.3
PEG Ratio 10.14
MYL's PEG Ratio is ranked lower than
90% of the 293 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.90 vs. MYL: 10.14 )
Ranked among companies with meaningful PEG Ratio only.
MYL' s PEG Ratio Range Over the Past 10 Years
Min: 0.74  Med: 2.75 Max: 13.61
Current: 10.14
0.74
13.61
Shiller PE Ratio 86.04
MYL's Shiller PE Ratio is ranked lower than
74% of the 161 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 43.67 vs. MYL: 86.04 )
Ranked among companies with meaningful Shiller PE Ratio only.
MYL' s Shiller PE Ratio Range Over the Past 10 Years
Min: 14.48  Med: 81.5 Max: 169.02
Current: 86.04
14.48
169.02
Current Ratio 1.49
MYL's Current Ratio is ranked lower than
74% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.55 vs. MYL: 1.49 )
Ranked among companies with meaningful Current Ratio only.
MYL' s Current Ratio Range Over the Past 10 Years
Min: 1.21  Med: 5.94 Max: 11.71
Current: 1.49
1.21
11.71
Quick Ratio 1.01
MYL's Quick Ratio is ranked lower than
78% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.85 vs. MYL: 1.01 )
Ranked among companies with meaningful Quick Ratio only.
MYL' s Quick Ratio Range Over the Past 10 Years
Min: 0.85  Med: 4.24 Max: 8.47
Current: 1.01
0.85
8.47
Days Inventory 130.79
MYL's Days Inventory is ranked lower than
57% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 117.29 vs. MYL: 130.79 )
Ranked among companies with meaningful Days Inventory only.
MYL' s Days Inventory Range Over the Past 10 Years
Min: 88.95  Med: 133.92 Max: 168.24
Current: 130.79
88.95
168.24
Days Sales Outstanding 99.36
MYL's Days Sales Outstanding is ranked lower than
66% of the 636 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.05 vs. MYL: 99.36 )
Ranked among companies with meaningful Days Sales Outstanding only.
MYL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 77.49  Med: 86.72 Max: 107.26
Current: 99.36
77.49
107.26
Days Payable 53.75
MYL's Days Payable is ranked lower than
65% of the 586 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.53 vs. MYL: 53.75 )
Ranked among companies with meaningful Days Payable only.
MYL' s Days Payable Range Over the Past 10 Years
Min: 50.24  Med: 70.84 Max: 101.21
Current: 53.75
50.24
101.21

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -12.90
MYL's 3-Year Average Share Buyback Ratio is ranked lower than
75% of the 442 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.30 vs. MYL: -12.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MYL' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -25.5  Med: -1 Max: 8.6
Current: -12.9
-25.5
8.6

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.23
MYL's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
82% of the 288 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.56 vs. MYL: 1.23 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
MYL' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.62  Med: 1.71 Max: 4.64
Current: 1.23
0.62
4.64
Price-to-Intrinsic-Value-DCF (Earnings Based) 3.63
MYL's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
98% of the 80 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.33 vs. MYL: 3.63 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.05
MYL's Price-to-Median-PS-Value is ranked higher than
60% of the 645 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.13 vs. MYL: 1.05 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MYL' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.37  Med: 2.18 Max: 6.6
Current: 1.05
0.37
6.6
Earnings Yield (Greenblatt) % 1.96
MYL's Earnings Yield (Greenblatt) % is ranked lower than
62% of the 1046 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.36 vs. MYL: 1.96 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MYL' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.3  Med: 5.1 Max: 19
Current: 1.96
1.3
19
Forward Rate of Return (Yacktman) % 8.90
MYL's Forward Rate of Return (Yacktman) % is ranked lower than
53% of the 369 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.72 vs. MYL: 8.90 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
MYL' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 7.9  Med: 13.5 Max: 24.9
Current: 8.9
7.9
24.9

More Statistics

Revenue (TTM) (Mil) $11,605
EPS (TTM) $ 1.02
Beta1.46
Short Percentage of Float3.80%
52-Week Range $33.60 - 50.40
Shares Outstanding (Mil)535.95

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 12,471 12,988 13,579
EPS ($) 5.19 5.64 6.27
EPS without NRI ($) 5.19 5.64 6.27
EPS Growth Rate
(Future 3Y To 5Y Estimate)
4.83%
Dividends per Share ($)
» More Articles for MYL

Headlines

Articles On GuruFocus.com
Theravance Biopharma and Mylan Report Additional Phase 3 Data for Revefenacin (TD-4208) in Several P May 23 2017 
Theravance Biopharma and Mylan Report Additional Phase 3 Data for Revefenacin (TD-4208) in Several P May 23 2017 
Mylan to Present at UBS Global Healthcare Conference May 16 2017 
Mylan Honors National Women's Health Week to Empower Women to Take Control of Their Health May 16 2017 
Citigroup, 21st Century Fox, Mylan, TripAdvisor Inc., and Zayo Group Holdings Inc. and more offer op May 11 2017 
Richard Pzena Invests in 3 Health Care Companies May 09 2017 
Mylan Nominates Sjoerd Vollebregt for Election to Board of Directors May 01 2017 
Mylan to Report First Quarter 2017 Financial Results on May 10, 2017 Apr 27 2017 
Mylan Launches Generic Trilafon Tablets Apr 20 2017 
Mylan Provides Update on Meridian Medical Technologies', a Pfizer Company, Expanded Voluntary Worldw Mar 31 2017 

More From Other Websites
Theravance Biopharma and Mylan Report Additional Phase 3 Data for Revefenacin (TD-4208) in Several... May 23 2017
It's Easy To Be Skeptical Of Mylan, But Don't Ignore This Pending PDUFA Date May 22 2017
Mylan Stock Gains Following Barclays Upgrade May 22 2017
Mylan N.V. -- Moody's assigns Baa3 to Mylan's euro notes offering; stable outlook May 17 2017
Theravance Biopharma and Mylan to Present Additional Data for Revefenacin (TD-4208) in Several... May 17 2017
Mylan Honors National Women's Health Week to Empower Women to Take Control of Their Health May 16 2017
3 Top Healthcare Stocks to Buy Now May 16 2017
EpiPens can stay potent for years after they expire May 13 2017
Tepper's Appaloosa Trims Bets on Pharmaceuticals May 12 2017
Health: EpiPen maker accused of overcharging for asthma drug May 12 2017
Why prescription drug prices keep going up May 12 2017
Pharma Stock Roundup: Mylan, Teva Q1 Earnings, Roche Drug Misses in Pivotal Study May 12 2017
Edited Transcript of MYL earnings conference call or presentation 10-May-17 2:00pm GMT May 11 2017
Company News for May 11, 2017 May 11 2017
EpiPen price hike was ‘intentional’: AllergyKids Founder May 10 2017
Mylan Q1 Revenue Falls Short Of Views As EpiPen Sales Decline May 10 2017
Mylan disagrees with FDA over generic Advair delay May 10 2017
Mylan edges past profit estimates May 10 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat